Sort
82,697 grants matching “vaccine development”
Chiang Mai University HIV/AIDS Clinical Trials Unit
$1,300,750Thira Sirisanthana · Chiang Mai University · U01 · FY2009 · AI
A Phase II Evaluation of the Safety and Protective Efficacy of the Live Attenuated Tetravalent Dengue Vaccine TetraVax-DV with Challenge by the Recombinant DENV-2 Virus in a Dengue Endemic Population
$1,300,717Beth Diane Kirkpatrick · University Of Vermont & St Agric College · U01 · FY2019 · AI
Host Defense Against HIV-related Pulmonary Infections
$1,300,680Judd E Shellito · Lsu Health Sciences Center · P01 · FY2007 · HL
Conserved Element DNA Vaccine
$1,300,391Barbara Felber · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Prevention of AIDS
$1,300,391Barbara Felber · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Dendritic Cell Biology and Therapy
$1,300,247University Of Pittsburgh At Pittsburgh · P01 · FY2004 · CA
HIV Vaccine Design and Development Teams
$1,300,000 · N01 · FY2007 · AI
HIV VACCINE DESIGN AND DEVELOPMENT TEAMS (HVDDT)
$1,300,000Mark Newman · · N01 · FY2007 · AI
Mandatory_Estimates of Vaccine Effectiveness Against Medically-Attended, PCR-Confirmed Influenza in West South Central U.S.
$1,300,000Manjusha Gaglani · Scott And White Memorial Hospital · U01 · FY2019 · IP
Prospective annual estimates of influenza vaccine effectiveness and burden of disease
$1,300,000Michael L Jackson · Kaiser Foundation Research Institute · U01 · FY2019 · IP
Prospective annual estimates of influenza vaccine effectiveness and burden of disease
$1,300,000Michael L Jackson · Kaiser Foundation Research Institute · U01 · FY2018 · IP
Prospective annual estimates of influenza vaccine effectiveness and burden of disease
$1,300,000Michael L Jackson · Kaiser Foundation Research Institute · U01 · FY2018 · IP
Mandatory_Estimates of Vaccine Effectiveness Against Medically-Attended, PCR-Confirmed Influenza in West South Central U.S.
$1,300,000Manjusha Gaglani · Scott And White Memorial Hospital · U01 · FY2018 · IP
US Influenza Vaccine Effectiveness Network
$1,299,999Arnold S Monto · University Of Michigan At Ann Arbor · U01 · FY2017 · IP
US Influenza Vaccine Effectiveness Network
$1,299,999Arnold S Monto · University Of Michigan At Ann Arbor · U01 · FY2016 · IP
Cell Prep Core
$1,299,944John Wunderlich · Division Of Basic Sciences - Nci · ZIC · FY2010 · CA
Cell Production Facility Core
$1,299,942Mark Dudley · Division Of Basic Sciences - Nci · ZIC · FY2010 · CA
ALABAMA/ZAMBIA HIV VACCINE CLINICAL TRIALS UNIT (HVTU)
$1,299,748University Of Alabama At Birmingham · U01 · FY2004 · AI
Cell Production Core Facility
$1,299,285Robert Somerville · Division Of Basic Sciences - Nci · ZIC · FY2017 · CA
Surgery Branch Cell Prep Core
$1,299,285John Wunderlich · Division Of Basic Sciences - Nci · ZIC · FY2017 · CA
RP2: Broad Spectrum SiRNA Marburg
$1,299,112Ian Maclachlan · University Of Texas Med Br Galveston · U19 · FY2015 · AI
IGF::OT::IGF NIAID PRECLINICAL DEVELOPMENT SUPPORT - PRODUCTION FEASIBILITY EVALUATION OF TECHNOLOGY TO MODULATE PROTEIN EXPRESSION CELLULAR PATHWAYS
$1,298,979Thomas Vancott · Advanced Bioscience Laboratories, Inc. · N01 · FY2016 · AI
Non-human primate (NHP) Core
$1,298,484Natasa Strbo · University Of Miami School Of Medicine · P01 · FY2011 · AI
Biologically informed design of CD8+ T cell-dependent pre-erythrocytic stage malaria vaccines
$1,298,298Stefan H.i. Kappe · Seattle Children'S Hospital · U01 · FY2022 · AI
Sirtuin -Dependent Regulation of Tuberculosis and HIV Interactions in Macrophages
$1,297,775Chinnaswamy Jagannath · Methodist Hospital Research Institute · R01 · FY2024 · AI